Bionomics Limited Performance
| BNOEFDelisted Stock | USD 0.01 0.00 0.00% |
The firm shows a Beta (market volatility) of 6.44, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bionomics will likely underperform. Bionomics Limited right now shows a risk of 0.0%. Please confirm Bionomics Limited total risk alpha, downside variance, day median price, as well as the relationship between the maximum drawdown and skewness , to decide if Bionomics Limited will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bionomics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical and fundamental indicators, Bionomics is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 28.5 M | |
| Total Cashflows From Investing Activities | 621.7 K |
Bionomics |
Bionomics Relative Risk vs. Return Landscape
If you would invest 1.31 in Bionomics Limited on August 29, 2024 and sell it today you would earn a total of 0.00 from holding Bionomics Limited or generate 0.0% return on investment over 90 days. Bionomics Limited is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Bionomics, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Bionomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bionomics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Bionomics Limited, and traders can use it to determine the average amount a Bionomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BNOEF |
Based on monthly moving average Bionomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bionomics by adding Bionomics to a well-diversified portfolio.
Bionomics Fundamentals Growth
Bionomics Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bionomics, and Bionomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bionomics Pink Sheet performance.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 27.83 M | |||
| Shares Outstanding | 1.35 B | |||
| Price To Earning | (34.09) X | |||
| Price To Book | 1.24 X | |||
| Price To Sales | 8.29 X | |||
| Revenue | 263.63 K | |||
| EBITDA | (21.92 M) | |||
| Cash And Equivalents | 33.56 M | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 693.62 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (21.76 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 65.31 M | |||
| Retained Earnings | (103 M) | |||
| Current Asset | 58 M | |||
| Current Liabilities | 11 M | |||
About Bionomics Performance
By analyzing Bionomics' fundamental ratios, stakeholders can gain valuable insights into Bionomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bionomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bionomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia. Bionomics is traded on OTC Exchange in the United States.Things to note about Bionomics Limited performance evaluation
Checking the ongoing alerts about Bionomics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bionomics Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bionomics Limited is not yet fully synchronised with the market data | |
| Bionomics Limited has some characteristics of a very speculative penny stock | |
| Bionomics Limited has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 263.63 K. Net Loss for the year was (21.76 M) with loss before overhead, payroll, taxes, and interest of (9.94 M). | |
| Bionomics Limited has accumulated about 33.56 M in cash with (21.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Bionomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bionomics' stock is overvalued or undervalued compared to its peers.
- Examining Bionomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bionomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bionomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bionomics' pink sheet. These opinions can provide insight into Bionomics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Bionomics Pink Sheet
If you are still planning to invest in Bionomics Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bionomics' history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |